Additional Documents

1 PDF: Answers to questions taken on notice by Cancer Council Australia at a public hearing on 31 January 2024; received 9 February 2024. Answers to questions taken on notice by Cancer Council Australia at a public hearing on 31 January 2024; received 9 February 2024.
2 PDF: Answers to questions taken on notice by Private Cancer Physicians of Australia at a public hearing on 31 January 2024; received 7 February 2024. Answers to questions taken on notice by Private Cancer Physicians of Australia at a public hearing on 31 January 2024; received 7 February 2024.
3 PDF: Answers to questions taken on notice by Sydney Children's Hospital Network at a public hearing on 31 January 2024; received 6 February 2024. Answers to questions taken on notice by Sydney Children's Hospital Network at a public hearing on 31 January 2024; received 6 February 2024.
4 PDF: Answers to questions taken on notice by Roche at a public hearing on 31 January 2024; received 5 February 2024. Answers to questions taken on notice by Roche at a public hearing on 31 January 2024; received 5 February 2024.
5 PDF: Answers to questions taken on notice by Australasian Leukaemia and Lymphoma Group at a public hearing on 1 February 2024; received 9 February 2024. Answers to questions taken on notice by Australasian Leukaemia and Lymphoma Group at a public hearing on 1 February 2024; received 9 February 2024.
6 PDF: Answers to questions taken on notice by NeuroEndocrine Cancer Australia at a public hearing on 1 February 2024; received 9 February 2024. Answers to questions taken on notice by NeuroEndocrine Cancer Australia at a public hearing on 1 February 2024; received 9 February 2024.
7 PDF: Answers to questions taken on notice by Cancer Trials Australia at a public hearing on 1 February 2024; received 6 February 2024. Answers to questions taken on notice by Cancer Trials Australia at a public hearing on 1 February 2024; received 6 February 2024.
8 PDF: Answers to questions taken on notice by Ipsen at a public hearing on 1 February 2024; received 13 February 2024. Answers to questions taken on notice by Ipsen at a public hearing on 1 February 2024; received 13 February 2024.
9 PDF: Answers to questions taken on notice by Ovarian Cancer Australia at a public hearing on 1 February 2024; received 9 February 2024. Answers to questions taken on notice by Ovarian Cancer Australia at a public hearing on 1 February 2024; received 9 February 2024.
10 PDF: Answers to questions taken on notice by The Royal Australian College of General Practitioners at a public hearing on 1 February 2024; received 16 February 2024. Answers to questions taken on notice by The Royal Australian College of General Practitioners at a public hearing on 1 February 2024; received 16 February 2024.
11 PDF: Answers to questions taken on notice by The Daffodil Centre, Sydney Cancer Partners at a public hearing on 31 January 2024; received 19 February 2024. Answers to questions taken on notice by The Daffodil Centre, Sydney Cancer Partners at a public hearing on 31 January 2024; received 19 February 2024.
12 PDF: Answers to questions taken on notice by the Department of Health and Aged Care at a public hearing on 1 March 2024; received 27 March 2024 Answers to questions taken on notice by the Department of Health and Aged Care at a public hearing on 1 March 2024; received 27 March 2024
13 PDF: Answers to questions taken on notice by Dr Melanie Wuttke and Dr Anna Johnston at a public hearing on 20 February 2024; received 26 April 2024 Answers to questions taken on notice by Dr Melanie Wuttke and Dr Anna Johnston at a public hearing on 20 February 2024; received 26 April 2024
14 PDF: Answers to questions taken on notice by Cancer Australia at a public hearing on 1 March 2024; received 13 March 2024. Answers to questions taken on notice by Cancer Australia at a public hearing on 1 March 2024; received 13 March 2024.
15 PDF: Answers to questions taken on notice by National Rural Health Alliance at a public hearing on 1 March 2024; received 15 March 2024. Answers to questions taken on notice by National Rural Health Alliance at a public hearing on 1 March 2024; received 15 March 2024.
16 PDF: Answers to questions taken on notice by Australian Teletrial Program at a public hearing on 1 March 2024; received 15 March 2024. Answers to questions taken on notice by Australian Teletrial Program at a public hearing on 1 March 2024; received 15 March 2024.
17 PDF: Answers to questions taken on notice by Rare Cancers Australia at a public hearing on 31 January 2024; received 15 February and 11 March 2024. Answers to questions taken on notice by Rare Cancers Australia at a public hearing on 31 January 2024; received 15 February and 11 March 2024.
18 PDF: Answers to questions taken on notice by Professor Jane Tiller at a public hearing on 1 February 2024; received 16 March 2024. Answers to questions taken on notice by Professor Jane Tiller at a public hearing on 1 February 2024; received 16 March 2024.

See Also

Other information presented to the inquiry

Committee Secretariat contact:

Committee Secretary
Senate Standing Committees on Community Affairs
PO Box 6100
Parliament House
Canberra ACT 2600

Phone: +61 2 6277 3515
community.affairs.sen@aph.gov.au

Inquiry Name

Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer



Past Public Hearings

09 Apr 2024: Adelaide
01 Mar 2024: Canberra
20 Feb 2024: Hobart

more...

Inquiry Status

Completed

Accessibility

We are committed to ensuring that everyone who wishes to can participate in the Committee’s inquiry. If you have accessibility requirements, please contact the Committee Secretariat.

Further information regarding accessibility can be found at www.aph.gov.au/Help/Accessibility